Hepatorenal syndrome
Revision as of 11:59, 14 March 2011 by Rossdonaldson1 (talk | contribs)
Pathophysiology
Functional renal vasoconstriction leading to severe redxn in GFR with minimal renal histologic abnormalities
Diagnosis
- Type 1: doubling of serum Cr to > 2.5mg/dl in < 2wk
- Type 2: stable or less rapidly progressive course than Type 1
- Type 1 & 2 both require^:
- Cr >1.5mg/dl
- Cr NOT reduced below 1.5mg/dl with administration of albumin (1g/kg) and after a minimum of 2 days off diuretics
- Abscence of current or recent rx with potentially nephrotoxic drugs
- Abscence of shock
- Abscence of renal parenchymal disease (urinary excretion of >500mg protein/d, >50 RBC/hpf, abnl kidneys on U/S)
DDx
- Hypovolemia-induced renal failure (GI bleed or fluid losses 2/2 diuretics, diarrhea most common)
- Parenchymal renal disease (proteinuria >500mg protein/d, >50 RBC/hpf or both; confirmed with renal biopsy)
- Drug-induced renal failure (current NSAIDs, aminoglycosides)
Treatment
- Vasoconstrictors
- Terlipressin: 0.5-1mg q 4-6 IV us 5-15d
- Norepi: 0.5-3mg/hr to increase MAP by 10mmHg
- Midrodrine: 7.5mg PO tid with Octreotide 100mcg sq
- Albumin: 1-1.5g/kg with one of above
- Other: TIPS, renal replacement therapy
Disposition
- 1-month survival: 50%
- 6-month survival: 20%
Source
Adapted from NEJM vol 361 no 13 P. Gines
^International Ascites Club criteria
